Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 7Other hematologic neoplasm 6Myeloid 5Thoracic 4Sarcoma 2Genitourinary 2Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
mocetinostat × Breast × Clear all
NCT00511576 2015-01-08

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Mirati Therapeutics Inc.

Phase 1 Terminated
54 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡